Junior Associate - Legal
Novo Nordisk is hiring a Junior Associate, Legal in Bengaluru to support their Global Legal, Intellectual Property, and Security department. The role focuses on ensuring regulatory compliance, conducting due diligence, and supporting legal processes through internal tools like COUPA and SharePoint. You will work with experienced legal professionals to manage global operations risk and support ethical business conduct. The ideal candidate has experience in legal departments of global corporations and strong contract management skills.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
2+ years
Function
Accounting
Work mode
Onsite, India
Company
Tier 2
What you will work on
Novo Nordisk is hiring a Junior Associate, Legal in Bengaluru to support their Global Legal, Intellectual Property, and Security department. The role focuses on ensuring regulatory compliance, conducting due diligence, and supporting legal processes through internal tools like COUPA and SharePoint. You will work with experienced legal professionals to manage global operations risk and support ethical business conduct. The ideal candidate has experience in legal departments of global corporations and strong contract management skills.
TAL's take
Solid multinational corporation with a clear, well-defined legal support role in a stable industry.
JD provides clear responsibilities, qualifications, and specific tools required for the role.
Salaries at Novo Nordisk
19.3 LPA average
Based on 19 Grapevine salary entries for Novo Nordisk.
Other roles
0 - 2 years
4 LPA average
Range: 4 - 4 LPA
Product Management
2 - 4 years | 6
14 LPA average
Range: 14 - 14 LPA
Other roles
2 - 4 years | 6
17 LPA average
Range: 17 - 17 LPA
Operations
4 - 6 years | L5
10 LPA average
Range: 10 - 10 LPA
Must haves
- Bachelors or master’s in law
- 2+ years of working experience in the legal department of global corporations
- Experience in contracts, legal and compliance matters, due diligence, and risk assessments
- Understanding of regulatory frameworks and compliance requirements
- Excellent contract drafting and negotiation skills
Tools and skills
About the company
Global pharmaceutical company with significant presence in India, but the GBS division functions as a global support unit.
Posts mentioning Novo Nordisk
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market. - Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs. - Retail investors remain bullish on Amgen despite analyst disappointment. Source: [Asianet Newsable](https://newsable.asianetnews.com/markets/amgen-stock-sinks-on-modest-obesity-drug-results-but-retail-sentiment-remains-steady-snk9xh), [Asianet Newsable](https://newsable.asianetnews.com/markets/eli-lilly-novo-nordisk-shares-climb-premarket-as-biden-administration-mulls-medicare-medicaid-covering-for-obesity-drugs-retail-unmoved-snk72g)
The Controversial Rise of Weight Loss Drugs
- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)
The Looming Fiscal Crisis Over Revolutionary Weight Loss Drugs
- America faces a fiscal crisis over revolutionary weight loss drugs like Ozempic and Wegovy. - These drugs, produced by Novo Nordisk, have potential cardiovascular, mental health, and anti-cancer benefits. - However, their high cost in the U.S. compared to other countries could bankrupt Medicare. - If half of U.S. adults with obesity took these drugs, it would cost $411 billion annually. - The State Treasurer of North Carolina, Dale Folwell, is questioning the high cost and has asked the federal government to negotiate with Novo Nordisk to open up patents to generic manufacturers. Source: [More Perfect Union](https://youtu.be/JqHmvMjXuro)